The Mass Tort Landscape in 2026: 198,000 Pending Cases Across the Top MDLs

There are 198,000 pending cases across all active MDLs as of January 2026, with over 342,000 total cases filed historically. Mass tort litigation is bigger than ever — and the landscape is shifting fast.

Here's a data-driven overview of where the action is, what's growing, and where the next opportunities lie.

The Active MDL Leaderboard

What's Growing Fastest

GLP-1 drugs are the clear growth leader. With 100+ new filings per month and two separate MDLs, this tort is on a trajectory that could rival PFAS within two years. Read our deep dive on GLP-1 gastroparesis litigation.

Hair relaxer litigation is approaching a critical moment. MDL 3060 alleges that hair straightening products from L'Oreal, Revlon, and others caused uterine, ovarian, and endometrial cancer — predominantly in Black and Brown women. Daubert motions are due April 1, 2026, and bellwether trials aren't expected until 2027. The outcome of the Daubert hearings will determine whether this becomes a billion-dollar tort or stalls.

Social media addiction represents a new category of mass tort entirely. Rather than pharmaceutical or chemical harm, these cases allege that addictive algorithms designed by Meta, TikTok, YouTube, and Snapchat caused anxiety, depression, eating disorders, and suicidal ideation in minors. This tort is still in its early stages but has enormous potential plaintiff exposure.

What's Resolving

Talc is entering its endgame. After three failed bankruptcy attempts, J&J faces open court litigation with escalating verdicts ($1.5 billion in December 2025). Settlement talks have formally begun. Firms with existing talc inventories should prepare for resolution within 12-24 months.

PFAS water contamination claims are substantially resolved via the 3M and DuPont settlements ($13 billion total). But individual health injury claims remain untried — that's the next chapter.

Where LEWS Sees Opportunity

Our system tracks 46 on-market products and 25+ known MDLs. Based on our multi-source signal analysis, we categorize opportunities as:

First-Mover (Pre-MDL): Products with strong adverse event signals but no consolidated litigation yet. These are the highest-value opportunities for plaintiff firms willing to invest early. Our system currently flags several products in this category beyond GLP-1.

Growth Phase (Active MDL, Growing): GLP-1 drugs, hair relaxers, social media. Case filings accelerating, but acquisition costs still manageable. Good entry points for firms building new practice areas.

Mature (Settlement Approaching): Talc, hernia mesh, PFAS water claims. Late-stage opportunities where the play is portfolio acquisition or MDL leadership positioning.

The Data Behind the Decisions

LEWS has ingested and analyzed:

• 18,500+ signals from 12 data sources
• 14,700+ medical research papers from PubMed
• 2,133 consumer complaints from Reddit and forums
• 619 court filings from CourtListener
• 547 FDA adverse event reports processed through FAERS
• 81,650 signal clusters identified by our AI clustering engine
• 173 scored litigation opportunities across six viability dimensions

Every number in this article is derived from data our system collected, classified, and scored automatically. That's what a legal early warning system does — it turns the fire hose of public data into actionable intelligence.

The Bottom Line

Mass tort litigation in 2026 is defined by two dynamics: mature torts reaching resolution (talc, PFAS water) and emerging torts accelerating rapidly (GLP-1, hair relaxers, social media). The firms that thrive are the ones with intelligence systems that help them see both at once — knowing when to harvest and when to plant.